Arcutis director sells 4,730 shares after option exercise

Q: What insider transactions did ARQT director Howard G. Welgus report on August 17, 2026?

Howard G. Welgus reported exercising options for 4,096 ARQT shares and selling 4,730 shares. The options had exercise prices of $6.5223, $7.51, and $8.63, while the sale used a weighted average price of $26.1807 per share.

Q: At what prices were the Arcutis Biotherapeutics (ARQT) stock options exercised by Howard G. Welgus?

Howard G. Welgus exercised ARQT stock options at $6.5223, $7.51, and $8.63 per share. These fully vested options converted into the same number of common shares, totaling 4,096 shares acquired through exercises on August 17, 2026.

Q: How many Arcutis Biotherapeutics (ARQT) shares did Howard G. Welgus sell and at what price?

He sold 4,730 ARQT common shares at a weighted average price of $26.1807 per share. The shares were sold in multiple transactions, with individual prices ranging from $26.10 to $26.25, as disclosed in the Form 4 footnote.

Q: How many ARQT stock options did Howard G. Welgus exercise according to the Form 4?

He exercised options covering 4,096 shares of ARQT common stock. These consisted of 822 shares at $6.5223, 1,019 shares at $7.51, and 2,255 shares at $8.63 per share, with the options disclosed as fully vested.

Arcutis Biotherapeutics, Inc. (ARQT) director Howard G. Welgus reported option exercises and a share sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) director Howard G. Welgus reported option exercises and a share sale. He exercised fully vested stock options covering 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, acquiring the same number of common shares. On the same date, he sold 4,730 shares of common stock at a weighted average price of $26.1807 per share, in multiple trades between $26.10 and $26.25, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 with a plan end date of June 15, 2027.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Welgus Howard G.

Role Director

Sold 4,730 shs ($124K)

Approx. gross sale proceeds $124K

Approx. exercise cost $32K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F3}	822	$0.00	$0.00
Exercise	Stock Option (right to buy) ^{F1, F3}	1,019	$0.00	$0.00
Exercise	Stock Option (right to buy) ^F3	2,255	$0.00	$0.00
Exercise	Common Stock ^F1	822	$6.5223	$5K
Exercise	Common Stock ^F1	1,019	$7.51	$8K
Exercise	Common Stock ^F1	2,255	$8.63	$19K
Sale	Common Stock ^{F1, F2}	4,730	$26.1807	$124K

Holdings After Transaction: Stock Option (right to buy) — 36,846 contracts (Direct); Common Stock — 36,475 shares (Direct)

Footnotes (3)

F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. The option is fully vested.

Key Figures

Options exercised: 4,096 shares Shares sold: 4,730 shares Weighted average sale price: $26.1807 per share +4 more

7 metrics

Options exercised 4,096 shares Total underlying common shares from option exercises on August 17, 2026

Shares sold 4,730 shares Common stock sale on August 17, 2026

Weighted average sale price $26.1807 per share Weighted average for 4,730 shares sold, with trades from $26.10 to $26.25

Option exercise price 1 $6.5223 per share Exercise price for 822-share stock option, fully vested

Option exercise price 2 $7.51 per share Exercise price for 1,019-share stock option, fully vested

Option exercise price 3 $8.63 per share Exercise price for 2,255-share stock option, fully vested

10b5-1 plan adoption date March 13, 2026 Adoption date of trading plan governing these transactions; plan ends June 15, 2027

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, fully vested

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported ... was effected pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

fully vested financial

"The option is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ARQT director Howard G. Welgus report on August 17, 2026?

Howard G. Welgus reported exercising options for 4,096 ARQT shares and selling 4,730 shares. The options had exercise prices of $6.5223, $7.51, and $8.63, while the sale used a weighted average price of $26.1807 per share.

At what prices were the Arcutis Biotherapeutics (ARQT) stock options exercised by Howard G. Welgus?

Howard G. Welgus exercised ARQT stock options at $6.5223, $7.51, and $8.63 per share. These fully vested options converted into the same number of common shares, totaling 4,096 shares acquired through exercises on August 17, 2026.

How many Arcutis Biotherapeutics (ARQT) shares did Howard G. Welgus sell and at what price?

He sold 4,730 ARQT common shares at a weighted average price of $26.1807 per share. The shares were sold in multiple transactions, with individual prices ranging from $26.10 to $26.25, as disclosed in the Form 4 footnote.

Were Howard G. Welgus’s ARQT trades made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 13, 2026. The plan has an end date of June 15, 2027, indicating the trades followed a pre-established schedule.

How many ARQT stock options did Howard G. Welgus exercise according to the Form 4?

He exercised options covering 4,096 shares of ARQT common stock. These consisted of 822 shares at $6.5223, 1,019 shares at $7.51, and 2,255 shares at $8.63 per share, with the options disclosed as fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/19/2026 - 04:57 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		M⁽¹⁾		822	A	$6.5223	37,931	D
Common Stock	08/17/2026		M⁽¹⁾		1,019	A	$7.51	38,950	D
Common Stock	08/17/2026		M⁽¹⁾		2,255	A	$8.63	41,205	D
Common Stock	08/17/2026		S⁽¹⁾		4,730	D	$26.1807⁽²⁾	36,475	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.5223	08/17/2026		M⁽¹⁾			822	⁽³⁾	11/20/2029	Common Stock	822	$0	7,396	D
Stock Option (right to buy)	$7.51	08/17/2026		M⁽¹⁾			1,019	⁽³⁾	05/31/2033	Common Stock	1,019	$0	9,163	D
Stock Option (right to buy)	$8.63	08/17/2026		M			2,255	⁽³⁾	06/14/2034	Common Stock	2,255	$0	20,287	D

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR